argenx SE
HealthcareNASDAQ:ARGX · NASDAQ Global Select
-$5.42 today
Vol 0.27M · Avg 0.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
17.6%
avg -14.8%
ROIC
14.3%
avg -15.1%
ROA
14.9%
avg -11.4%
Analysis
ROE is currently the strongest return metric at 17.6% versus its period average of -14.8%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Karen Massey | Chief Executive Officer & Executive Director | $2.61M | — | 47 | — | — |
Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Executive Chairman of the Board | $1.63M | — | 54 | — | — |
Karl Gubitz | Chief Financial Officer | $1.00M | — | 56 | — | — |
Hans de Haard Ir | Co-Founder & Member of Board Advisors | — | — | 66 | — | — |
Filip Borgions | Chief Technology Innovation Officer | — | — | — | — | — |
Achim Plueckebaum | Global Head of Digital Technologies | — | — | — | — | — |
Malini Moorthy | General Counsel & Corporate Secretary | — | — | 56 | — | — |
Luc Truyen | Chief Medical Officer | — | — | 61 | — | — |
Peter Ulrichts | Chief Scientific Officer | — | — | 46 | — | — |
Arjen Lemmen | Vice President of Corporate Development & Strategy | — | — | 41 | — | — |
Andria Wilk | Global Head of Quality | — | — | 52 | — | — |
Sandrine Piret-Gerard | Chief Commercialization Officer | — | — | — | — | — |
Marc Schorpion | Global Head of Human Resources | — | — | 67 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +50.8% | +62.7% (15yr)10 analysts |
| Net Income | N/A | N/A | N/A | N/A10 analysts |
| EBIT | N/A | N/A | N/A | N/A10 analysts |
Analysis
Recent growth has been strongest in Revenue at +50.8% over three years. Forward estimates point to Revenue at +62.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.06B
Becton, Dickinson and Company
NYSE:BDX
$52.98B
Cardinal Health, Inc.
NYSE:CAH
$52.43B
Edwards Lifesciences Corporation
NYSE:EW
$49.01B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.24B
Haleon plc
NYSE:HLN
$40.31B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.76B
Agilent Technologies, Inc.
NYSE:A
$36.67B
Alcon Inc.
NYSE:ALC
$32.58B
Veeva Systems Inc.
NYSE:VEEV
$25.92B
Who manages ARGX?
argenx SE (ARGX) lists 13 active executives. The top listed executive is Karen Massey, Chief Executive Officer & Executive Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.